Hémangiome sclérosant du poumon : Questions médicales fréquentes
Nom anglais: Pulmonary Sclerosing Hemangioma
Descriptor UI:D047868
Tree Number:C08.785.520.867
Termes MeSH sélectionnés :
Lymph Node Excision
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hémangiome sclérosant du poumon : Questions médicales les plus fréquentes",
"headline": "Hémangiome sclérosant du poumon : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hémangiome sclérosant du poumon : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-17",
"dateModified": "2025-04-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs du poumon",
"url": "https://questionsmedicales.fr/mesh/D008175",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du poumon",
"code": {
"@type": "MedicalCode",
"code": "D008175",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C08.785.520"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon",
"alternateName": "Pulmonary Sclerosing Hemangioma",
"code": {
"@type": "MedicalCode",
"code": "D047868",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Weidong Zhang",
"url": "https://questionsmedicales.fr/author/Weidong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Cardiothoracic Surgery, Henan Provincial Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, Henan, China. zhangweidong0371@126.com."
}
},
{
"@type": "Person",
"name": "Tae Wook Kang",
"url": "https://questionsmedicales.fr/author/Tae%20Wook%20Kang",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dong Ik Cha",
"url": "https://questionsmedicales.fr/author/Dong%20Ik%20Cha",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Seong Hyun Kim",
"url": "https://questionsmedicales.fr/author/Seong%20Hyun%20Kim",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dan Song",
"url": "https://questionsmedicales.fr/author/Dan%20Song",
"affiliation": {
"@type": "Organization",
"name": "Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "N1 lymph node detection in lymph node harvesting in non-small cell lung cancer: Formaldehyde exposure is a drawback?",
"datePublished": "2023-10-10",
"url": "https://questionsmedicales.fr/article/37817262",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13019-023-02380-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node.",
"datePublished": "2022-09-21",
"url": "https://questionsmedicales.fr/article/36129636",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12282-022-01400-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lymph nodes: at the intersection of cancer treatment and progression.",
"datePublished": "2023-05-04",
"url": "https://questionsmedicales.fr/article/37149414",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tcb.2023.04.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "National Practice Patterns in the Management of the Regional Lymph Node Basin After Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36006494",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12364-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Management of Bulky Inguinal and Pelvic Lymph Nodes.",
"datePublished": "2024-05-18",
"url": "https://questionsmedicales.fr/article/38925736",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ucl.2024.03.012"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012140"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012142"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du poumon",
"item": "https://questionsmedicales.fr/mesh/D008175"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hémangiome sclérosant du poumon",
"item": "https://questionsmedicales.fr/mesh/D047868"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hémangiome sclérosant du poumon - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hémangiome sclérosant du poumon",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hémangiome sclérosant du poumon",
"description": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?\nQuels examens sont recommandés pour confirmer le diagnostic ?\nLes symptômes influencent-ils le diagnostic ?\nPeut-on confondre cette tumeur avec d'autres lésions ?\nQuel rôle joue la biopsie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Lymph+Node+Excision&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hémangiome sclérosant du poumon",
"description": "Quels sont les symptômes courants de l'hémangiome sclérosant ?\nL'hémangiome sclérosant cause-t-il des difficultés respiratoires ?\nPeut-on avoir des symptômes sans lésion visible ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Lymph+Node+Excision&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hémangiome sclérosant du poumon",
"description": "Peut-on prévenir l'hémangiome sclérosant du poumon ?\nY a-t-il des facteurs de risque connus ?\nLes habitudes de vie influencent-elles le risque ?\nLes examens réguliers aident-ils à la détection précoce ?\nLes femmes sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Lymph+Node+Excision&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hémangiome sclérosant du poumon",
"description": "Quel est le traitement standard pour l'hémangiome sclérosant ?\nPeut-on traiter cette condition par des médicaments ?\nQuand est-il nécessaire de surveiller sans traiter ?\nQuels sont les risques associés à la chirurgie ?\nY a-t-il des traitements alternatifs ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Lymph+Node+Excision&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hémangiome sclérosant du poumon",
"description": "Quelles complications peuvent survenir ?\nL'hémangiome peut-il se transformer en cancer ?\nComment gérer les complications respiratoires ?\nLes complications sont-elles fréquentes ?\nY a-t-il des complications post-chirurgicales ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Lymph+Node+Excision&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hémangiome sclérosant du poumon",
"description": "Quels sont les principaux facteurs de risque ?\nL'exposition à des toxines augmente-t-elle le risque ?\nLes antécédents médicaux influencent-ils le risque ?\nLe tabagisme est-il un facteur de risque ?\nLes facteurs génétiques jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Lymph+Node+Excision&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie, notamment la tomodensitométrie (TDM) et la biopsie."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "La TDM thoracique et l'IRM peuvent aider à visualiser la lésion et son caractère bénin."
}
},
{
"@type": "Question",
"name": "Les symptômes influencent-ils le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent être absents, rendant le diagnostic souvent incident lors d'examens pour d'autres raisons."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette tumeur avec d'autres lésions ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres tumeurs pulmonaires, nécessitant une analyse approfondie."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet de confirmer la nature bénigne de la lésion et d'exclure d'autres pathologies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de l'hémangiome sclérosant ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, il peut provoquer une toux ou des douleurs thoraciques dans certains cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome sclérosant cause-t-il des difficultés respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des complications peuvent entraîner des difficultés respiratoires dans certains cas."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans lésion visible ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes peuvent survenir sans lésion visible, rendant le diagnostic plus complexe."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes ne varient pas significativement selon l'âge, car la plupart des cas sont asymptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez la toux persistante ou des douleurs thoraciques, bien que souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'hémangiome sclérosant du poumon ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de mesures préventives spécifiques pour cette condition bénigne."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque connus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas clairement établis, mais des antécédents familiaux peuvent jouer un rôle."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve directe ne lie les habitudes de vie au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la détection précoce ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers peuvent aider à détecter des anomalies, mais l'hémangiome est souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent une prévalence plus élevée chez les femmes, mais les données sont limitées."
}
},
{
"@type": "Question",
"name": "Quel est le traitement standard pour l'hémangiome sclérosant ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est généralement chirurgical si la tumeur est symptomatique ou suspecte."
}
},
{
"@type": "Question",
"name": "Peut-on traiter cette condition par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement médicamenteux spécifique, la chirurgie est la principale option."
}
},
{
"@type": "Question",
"name": "Quand est-il nécessaire de surveiller sans traiter ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Si la tumeur est asymptomatique et bénigne, une surveillance régulière peut suffire."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés à la chirurgie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des saignements et des complications respiratoires post-opératoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements alternatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements alternatifs ne sont pas prouvés efficaces et ne remplacent pas la chirurgie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections pulmonaires et des hémorragies dans de rares cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome peut-il se transformer en cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'hémangiome sclérosant est une tumeur bénigne et ne se transforme pas en cancer."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications respiratoires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications respiratoires doivent être traitées symptomatiquement et surveillées attentivement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares, la plupart des cas étant asymptomatiques et sans incidents."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications post-chirurgicales ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des infections ou des saignements peuvent survenir après la chirurgie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas bien définis, mais des antécédents familiaux peuvent être impliqués."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines augmente-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve solide ne lie l'exposition à des toxines au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents médicaux ne semblent pas avoir d'impact direct sur le développement de cette tumeur."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le lien entre tabagisme et hémangiome sclérosant n'est pas clairement établi dans la littérature."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que des facteurs génétiques peuvent influencer le développement de l'hémangiome."
}
}
]
}
]
}
This study aimed to evaluate the effect of lymph node dissection method on staging results, diagnosis of tumor metastasis in single or multiple N1 lymph nodes and survival rates in patients with non-s...
Patients with NSCLC who underwent anatomic resection between September 2014 and October 2019 were examined prospectively. All patients with similar clinico-demographic characteristics were randomly as...
There were no significant differences in N1 lymph node positivity between the two groups (p = 0.482). On average 9.08 lymph node sampling was performed in the surgical group and 2.39 in the pathology ...
It is easier to detect lymph node involvement without introducing formaldehyde into the sample. We recommend that N1 lymph node dissection be performed on fresh specimens to detect more lymph node inv...
Little is known about the host-tumor interaction in the lymph-node basin at a single cell level. This study examines single cell sequences in breast cancer nodal metastases of a patient with triple-ne...
The primary breast tumor, sentinel lymph node, an adjacent lymph node with metastatic involvement and a clinically normal-appearing lymph node were collected during surgery. Single-cell sequencing was...
14,016 cells were clustered into 6 cell subpopulations. Cancer cells demonstrated the molecular characteristics of TNBC basal B subtype and highly expressed genes in the MAPK signaling cascade. Tumor-...
Single-cell sequencing analysis suggested that the sentinel lymph node was the initial meeting site of tumor infiltration and immune response, where partial T lymphocytes perform anti-tumor activity, ...
Metastasis to lymph nodes (LNs) is a common feature of disease progression in most solid organ malignancies. Consequently, LN biopsy and lymphadenectomy are common clinical practices, not only because...
Immediate completion lymph node dissection (CLND) for patients with sentinel lymph node (SLN) metastasis from cutaneous melanoma has been replaced largely by ultrasound nodal surveillance since the pu...
Patients with a diagnosis of cutaneous melanoma in 2016 and 2018 without clinical nodal disease who underwent sentinel lymph node biopsy (SLNB) were identified from the National Cancer Database (NCDB)...
Of the 3517 patients included in the study, 1405 had disease diagnosed in 2016. The patients with cutaneous melanoma diagnosed in 2016 had a median age of 60 years and a tumor thickness of 2.3 mm comp...
The rates of CLND have decreased nationally. However, patients with head/neck primary tumors who live in rural locations are more likely to undergo CLND, highlighting populations for which treatment m...
Penile cancer with bulky inguinal metastasis has a high probability of harboring pathologically involved lymph nodes best managed in a multidisciplinary care setting. Appropriate staging with cross-se...
In solid tumors, the detection of locoregional lymph node metastases is of decisive importance not only for the prognosis but also for selecting the correct treatment. Various noninvasive imaging meth...
This article presents the general principles of noninvasive lymph node diagnostics and discusses the value of the clinically available imaging modalities, ultrasound (US), computed tomography (CT), ma...
Literature search and summary of the clinical and scientific experience of the authors....
The available imaging procedures are divided into (1) morphological (US, CT, MRI) and (2) functional modalities (PET, special MRI). The former capture structural lymph node parameters, such as size an...
Currently, none of the available modalities have sufficient accuracy to replace lymph node dissection in all oncological scenarios. One of the major challenges for interdisciplinary oncological resear...
A primary colorectal cancer (CRC) tumor can contain heterogeneous cancer cells. As clones of cells with different properties metastasize to lymph nodes (LNs), they could show different morphologies. C...
Our study enrolled 318 consecutive patients with CRC who underwent primary tumor resection with lymph node dissection between January 2011 and June 2016. 119 (37.4%) patients who had metastatic LNs (m...
The histologies of the cancer cells in the mLNs were classified into four types: tubular, cribriform, poorly differentiated, and mucinous. Same degree of pathologically diagnosed differentiation in th...
Histology in LNM from CRC might indicate the heterogeneity and malignant phenotype of the disease....
Hepatic alveolar echinococcosis (AE) is a severe zoonotic parasitic disease, and accurate preoperative prediction of lymph node (LN) metastasis in AE patients is crucial for disease management, but it...
A total of 100 hepatic AE patients who underwent hepatectomy and hepatoduodenal ligament LN dissection at Qinghai Provincial People's Hospital between January 2016 and August 2023 were included in the...
A total of 7 radiomics features associated with LN status were selected using LASSO regression. The classification performances of the training set and validation set were consistent, with area under ...
In this study, we established and evaluated a radiomics-based prediction model for LN metastasis in patients with hepatic AE using CT imaging. Our findings may provide a valuable reference for clinici...
To evaluate the role of unilateral inguinal lymph-node dissection (ILND) plus contralateral dynamic sentinel node biopsy (DSNB) vs. bilateral ILND in clinical N1 (cN1) penile squamous cell carcinoma (...
Within our institutional database (1980-2020, included), we identified 61 consecutive cT1-4 cN1 cM0 patients with histological confirmed peSCC who underwent either unilateral ILND plus DSNB (26) or bi...
Median age was 54 years (Interquartile range [IQR]: 48-60 years). Median follow-up was 68 months (IQR 21-105 months). Most patients had pT1 (23 %) or pT2 (54.1%), as well as G2 (47.5%) or G3 (23%) tum...
In patients with cN1 peSCC the risk of occult contralateral nodal disease is comparable to cN0 high risk peSCC and the gold standard, namely bilateral ILND, may be replaced by unilateral ILND and cont...
Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) for assessing axillary lymph node status in clinically node-negative breast cancer patients. However, the approach ...
After NAC, 150 clinically node-negative patients were included. The relationships between clinicopathologic parameters and the number of positive lymph nodes in SLNBs and ALNDs were assessed through b...
Among 150 patients, 78 patients had negative SLNBs, and 72 patients had positive SLNBs. According to the ALND data of 21 patients with SLNB1+, there was no additional node involvement (80.8%), 1-2 lym...
The number of SLNB-positive nodes, tumor-related parameters, and response to treatment may predict no additional nodes to be positive at ALND....